Tvardi Therapeutics, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -76.6% | +233.7% | -19.5% | -29.2% | -14.6% | -36.5% | +57.3% | -10.8% | -17.8% | -19.5% | -32.1% | |
| – | -74.0% | +210.5% | -21.4% | -25.0% | -8.5% | -46.5% | +83.9% | -10.9% | -18.0% | -19.7% | -32.6% | |
| – | -63.8% | +105.1% | +4.8% | -21.7% | -1.7% | -69.8% | +80.5% | +3.7% | -3.2% | -4.3% | -20.6% | |
| – | -71.0% | +204.4% | -18.9% | -23.1% | -12.9% | -41.1% | +83.7% | -11.1% | -15.5% | -18.9% | -36.9% | |
| – | -29.9% | -27.3% | -37.7% | -24.8% | +228.3% | -50.2% | – | – | – | – | – | |
| – | – | – | -40.0% | -62.0% | +44.0% | +0.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -4.0% | -4.2% | -4.1% | -4.5% | -4.7% | -5.0% | -4.9% | |
| – | +199.9% | -32.3% | +1.0% | -16.9% | -4.3% | -11.3% | -74.8% | +3.1% | -0.3% | +1.7% | -19.2% | |
| – | -85.7% | +360.1% | -7.9% | -27.8% | -60.4% | +76.2% | +52.6% | +3.4% | +0.0% | +2.0% | -19.1% | |
| – | -81.3% | +136.6% | -23.6% | +1,933.9% | – | – | +2.8% | +3.7% | +2.7% | +3.4% | +2.5% | |
| – | -79.8% | +209.0% | +35.7% | -62.4% | -43.6% | +17.6% | +43.8% | +68.2% | -21.1% | +43.5% | +0.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -172.5% | – | -61.1% | -93.9% | -749.6% | – | – | -15.4% | -24.8% | -30.8% | -42.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +521.0% | +0.0% | -83.8% | +0.2% | +0.0% | +514.0% | -9.6% | +10.9% | +0.0% | +0.0% | +0.0% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.